by Clinical Neuropsychologist Online | Saturday, August 8, 2026 | Dementia
Abstract INTRODUCTION Dysfunctional microRNAs and GABAergic interneurons are features of Alzheimer’s disease (AD). The role of neuronal microRNA155 (miR155), elevated in both AD and Down syndrome (DS), remains unknown. METHODS We utilized in silico analyses of...
by Clinical Neuropsychologist Online | Saturday, August 8, 2026 | Dementia
Abstract Over the past decade, the Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) consortium has transformed preclinical Alzheimer’s disease (AD) research by addressing critical limitations in traditional mouse...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION Limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy neuropathological change (LATE-NC) is a cause of dementia resembling Alzheimer’s disease (AD). The 90+ Study found women using hormone...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION This analysis of the phase 3 TRAILBLAZER-ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p-tau217) level can reliably monitor treatment-related amyloid clearance (TRAC) after donanemab treatment in early...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION Sleep disturbances are frequent symptoms of Alzheimer’s disease (AD), mirrored by early pathology in the dorsal raphe nucleus (DRN). Whether early DRN pathology can drive sleep disturbances, and the relative contributions of serotonin...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION ABBV-916, an anti-amyloid immunotherapy, was evaluated in patients with early Alzheimer’s disease (AD). METHODS This phase 1b/2, double-blind, placebo-controlled study consisted of two stages: multiple ascending dose (Stage A) and dose...
